G9a Is SETting the Stage for Colorectal Oncogenesis.

Christopher J Bergin, Yannick D Benoit

Open access · goldAbstract read

In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.3field-weighted citation impact, top 46% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.Cancers · 2022
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Christopher J BerginDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

Yannick D BenoitDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

University of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, Kato et al. reported recurrent activating mutations in the SET domain of histone methyltransferase G9a, driving an oncogenic cascade in melanoma. The authors also reported correlations between G9a expression and the regulation of the canonical WNT pathway. Although we could not observe such mutations in human colorectal adenocarcinoma, newly reported findings are of high relevance to colorectal cancer, as WNT target gene signatures were closely associated with G9a expression. Here, we put into perspective such new results on G9a expression in colorectal cancers and the potential relationship with tumor heterogeneity and acquisition of neoplastic stemness.

Indexed as

Genetic HeterogeneityCarcinogenesisColorectal NeoplasmsGene Expression Regulation, NeoplasticHistocompatibility AntigensHistone-Lysine N-MethyltransferaseHumansMaleMutationNeoplastic Stem CellsPR-SET DomainsWnt ProteinsEHMT2 protein, humanHistocompatibility AntigensHistone-Lysine N-MethyltransferaseWnt Proteinscancer stem cellscolorectal cancerdriving mutationsepigeneticsG9a

Identifiers

PMID32512705

DOI10.3390/genes11060616

PMCPMC7349591

OpenAlexW3033455367

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.